4BIO Capital Leads £61 Million Series A to Advance Cytospire’s Gamma Delta T-Cell Engagers

New updates have been reported about 4BIO Capital.

4BIO Capital has strengthened its oncology portfolio by leading an oversubscribed £61 million ($83 million) Series A round for Cytospire Therapeutics, underscoring its strategy to back differentiated immuno-oncology platforms with clear clinical paths. The financing, supported by a broad syndicate of new and existing life sciences investors, will fund advancement of Cytospire’s first-in-class pan-gamma delta T-cell engager pipeline, including lead candidate CYT X300 through IND-enabling work and into initial human trials for EGFR-positive solid tumors.

For 4BIO Capital, the round both consolidates its role as Cytospire’s key financial and strategic backer and validates its investment thesis around next-generation immune cell engagers with improved safety and efficacy versus conventional CD3 T-cell approaches. Partner Owen Smith, who serves on Cytospire’s board, highlighted that the company’s early data and experienced management team align with 4BIO’s focus on translating high-conviction science into clinical assets, potentially driving step-change value as CYT X300 approaches first-in-human studies. The syndicated round also broadens Cytospire’s investor base with global specialist funds, which may de-risk future financing and create optionality for 4BIO on exit routes, while giving the firm increased influence over development milestones and strategic direction in a high-need segment of solid tumor oncology.